Implications and reasons for the lack of use of reperfusion therapy in patients with ST-segment elevation myocardial infarction: Findings from the CRUSADE initiative

American Heart Journal

Volumn 159, Issue 5, 2010, Pages 757-763

  Gharacholou, Shahyar Michael ^a   Alexander, Karen P ^a   Chen, Anita Y ^a   Wang, Tracy Y ^a   Melloni, Chiara ^a   Gibler, W Brian ^b   Pollack Jr , Charles V ^c   Ohman, E Magnus ^a   Peterson, Eric D ^a   Roe, Matthew T ^a  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^c PENNSYLVANIA HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; FIBRINOLYTIC AGENT; LOW MOLECULAR WEIGHT HEPARIN;

ADULT; AGE; ARTICLE; BLEEDING; COMORBIDITY; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; FEMALE; HEART CATHETERIZATION; HEART FAILURE; HEART MUSCLE REPERFUSION; HEART MUSCLE REVASCULARIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PATIENT CODING; PATIENT SELECTION; PRIORITY JOURNAL; SEX DIFFERENCE; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STROKE; TOTAL QUALITY MANAGEMENT; TREATMENT CONTRAINDICATION; UNITED STATES;

AGED; FEMALE; GUIDELINE ADHERENCE; HOSPITAL MORTALITY; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES AS TOPIC; QUALITY INDICATORS, HEALTH CARE; REGISTRIES; UNITED STATES;

EID: 77951650991     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2010.02.009     Document Type: Article

References (16)

1. Antman E.M., Anbe D.T., Armstrong P.W., et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of Patients with Acute Myocardial Infarction). J Am Coll Cardiol 44 (2004) e1-e211
2. Canadian Cardiovascular Society, American Academy of Family Physicians, American College of Cardiology, et al. Focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2008;51 (2007) 210-247
3. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet 343 (1994) 311-322
4. The Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes (GUSTO IIb) Angioplasty Substudy Investigators. A clinical trial comparing primary coronary angioplasty with tissue plasminogen activator for acute myocardial infarction. N Engl J Med 336 (1997) 1621-1628
5. Centers for Medicare and Medicaid Services and The Joint Commission. Specifications manual for national hospital quality measures. Available at:. http://www.qualitynet.org/dcs/ContentServer?c=Page&pagename=QnetPubl ic%2FPage%2FQnetTier2&cid=1141662756099 Last accessed on October 30, 2009
6. The Joint Commission. Acute myocardial infarction core measures set. Available at:. http://www.jointcommission.org/PerformanceMeasurement/PerformanceMeasure ment/Acute+Myocardial+Infarction+Core+Measure+Set.htm Last accessed on October 30, 2009
7. Masoudi F.A., Bonow R.O., Brindis R.G., et al. ACC/AHA Task Force on Performance Measures. ACC/AHA 2008 statement on performance measurement and reperfusion therapy: a report of the ACC/AHA Task Force on Performance Measures (Work Group to Address the Challenges of Performance Measurement and Reperfusion Therapy). Circulation 118 (2008) 2649-2661
8. Gibson C.M., Pride Y.B., Frederick P.D., et al. Trends in reperfusion strategies, door-to-needle and door-to-balloon times, and in-hospital mortality among patients with ST-segment elevation myocardial infarction enrolled in the National Registry of Myocardial Infarction from 1990 to 2006. Am Heart J 156 (2008) 1035-1044
9. Eagle K.A., Nallamothu B.K., Mehta R.H., et al. Trends in acute reperfusion therapy for ST-segment elevation myocardial infarction from 1999 to 2006: we are getting better but we have got a long way to go. Eur Heart J 29 (2008) 609-617
10. Barron H.V., Bowlby L.J., Breen T., et al. Use of reperfusion therapy for acute myocardial infarction in the United States: data from the National Registry of Myocardial Infarction 2. Circulation 97 (1998) 1150-1156
11. Eagle K.A., Goodman S.G., Avezum A., et al. Practice variation and missed opportunities for reperfusion in ST-segment-elevation myocardial infarction: findings from the Global Registry of Acute Coronary Events (GRACE). Lancet 359 (2002) 373-377
12. Zeger S.L., and Liang K.Y. Longitudinal data analysis for discrete and continuous outcomes. Biometrics 42 (1986) 121-130
13. French J.K., Williams B.F., Hart H.H., et al. Prospective evaluation of eligibility for thrombolytic therapy in acute myocardial infarction. BMJ 312 (1996) 1637-1641
14. Alter D.A., Ko D.T., Newman A., et al. Factors explaining the under-use of reperfusion therapy among ideal patients with ST-segment elevation myocardial infarction. Eur Heart J 27 (2006) 1539-1549
15. Grzybowski M., Clements E.A., Parsons L., et al. Mortality benefit of immediate revascularization of acute ST-segment elevation myocardial infarction in patients with contraindication to thrombolytic therapy. JAMA 290 (2003) 1891-1898
16. Kutcher M.A., Klein L.W., Ou F.S., et al. Percutaneous coronary interventions in facilities without cardiac surgery on site: a report from the National Cardiovascular Data Registry (NCDR). J Am Coll Cardiol 54 (2009) 16-24